Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lunai Bioworks (Nasdaq:LNAI) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lunai Bioworks (Nasdaq:LNAI) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq staff had notified the company on April 14, 2025 that LNAI's common stock failed to maintain a $1.00 minimum bid over the prior 30 business days. Staff determined the closing bid price was at or above $1.00 for 11 consecutive business days from September 30, 2025 through October 14, 2025, restoring compliance and leaving the company eligible to remain listed on The Nasdaq Capital Market. Management said the milestone supports its focus on advancing an AI-powered platform for drug discovery and biodefense.
Positive
- Regained Nasdaq compliance after 11 consecutive business days at or above $1.00
- Remains eligible for continued listing on The Nasdaq Capital Market
Negative
- Notified on April 14, 2025 of prior failure to maintain $1.00 minimum bid
Details
News Market Reaction – LNAI
On Oct 16, the day this news came out, LNAI closed 1.61% below the previous close.
Data tracked by StockTitan Argus for the Oct 16 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.
On April 14, 2025, Nasdaq Staff notified the Company that its common stock had failed to maintain a minimum bid price of
"This compliance milestone reflects our commitment to strategic execution and shareholder value during a transformative period for Lunai Bioworks," said David Weinstein, Chief Executive Officer. "We remain focused on advancing our AI-powered platform and delivering long-term impact across drug discovery and biodefense."
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Media Contact:
David Weinstein
Chief Executive Officer
305-918-1980
ir@lunaibioworks.com
http://www.lunaibioworks.com/
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.